Journal: PLoS ONE

Article Title: Nuclear Expression of KLF6 Tumor Suppressor Factor Is Highly Associated with Overexpression of ERBB2 Oncoprotein in Ductal Breast Carcinomas

doi: 10.1371/journal.pone.0008929

Figure Lengend Snippet: Immunohistochemistry assays in two lots of Tumor tissues Microarray from DAKO (CheckBoard Tissue Tumor human Tissues, T1064, Dako, USA). Tissues were incubated with anti-KLF6 (clone 2C11, left panel ) or anti-ERBB2 ( right panel ) antibodies. Lot 1 (#00071) is represented in the panel L1, and Lot 2 (#00111) in panels L2a, L2b and L2c. The KLF6 and ERBB2 stains were photographed in the equivalent area of the tissue section at 400× of magnification.

Article Snippet: A significant subpopulation of the ductal breast tumor collection [44% (21/48)] showed positive immunostain for nuclear KLF6 and ERBB2 overexpression (Chi-square and Fisher exact tests p values equal to 0.005 and 0.003, respectively; ); analysis of the tumor population overexpressing only ERBB2 revealed that the seventy-eight percent (21/27) of ductal breast tumor tissues expressed nuclear KLF6 ( ).

Techniques: Immunohistochemistry, Microarray, Incubation

Journal: PLoS ONE

Article Title: Nuclear Expression of KLF6 Tumor Suppressor Factor Is Highly Associated with Overexpression of ERBB2 Oncoprotein in Ductal Breast Carcinomas

doi: 10.1371/journal.pone.0008929

Figure Lengend Snippet: Immunohistochemistry assays in LandMark LD Breast TMA tissue microarray (Ambion, Austin, TX, USA). Tissues were incubated with the anti-KLF6 and anti-ERBB2 antibodies. The left panel of the KLF6 and ERBB2 column pictures has 400× magnification. The square into each 400× picture indicates the area photographed at 1000× and showed in the right panel of each column. Photomicrographs of the immunostain for KLF6 and ERBB2 were taken from equivalent tissue areas. The horizontal panels represents the KLF6 and ERBB2 expression in a fibroadenoma tissue ( i ) and four representative cases for both positive nuclear KLF6 and ERBB2 ( ii ), negative nuclear KLF6 and positive ERBB2 ( iii ), positive nuclear KLF6 and negative ERBB2 ( iv ), and both negative nuclear KLF6 and ERBB2 ( v ). Tissues in ii–v correspond to the cases 40, 18, 45, and 6, respectively, described in and .

Article Snippet: A significant subpopulation of the ductal breast tumor collection [44% (21/48)] showed positive immunostain for nuclear KLF6 and ERBB2 overexpression (Chi-square and Fisher exact tests p values equal to 0.005 and 0.003, respectively; ); analysis of the tumor population overexpressing only ERBB2 revealed that the seventy-eight percent (21/27) of ductal breast tumor tissues expressed nuclear KLF6 ( ).

Techniques: Immunohistochemistry, Microarray, Incubation, Expressing

Journal: PLoS ONE

Article Title: Nuclear Expression of KLF6 Tumor Suppressor Factor Is Highly Associated with Overexpression of ERBB2 Oncoprotein in Ductal Breast Carcinomas

doi: 10.1371/journal.pone.0008929

Figure Lengend Snippet: Analysis of KLF6 and HER2-ERBB2 proteins in breast tumor tissues.

Article Snippet: A significant subpopulation of the ductal breast tumor collection [44% (21/48)] showed positive immunostain for nuclear KLF6 and ERBB2 overexpression (Chi-square and Fisher exact tests p values equal to 0.005 and 0.003, respectively; ); analysis of the tumor population overexpressing only ERBB2 revealed that the seventy-eight percent (21/27) of ductal breast tumor tissues expressed nuclear KLF6 ( ).

Techniques:

Journal: PLoS ONE

Article Title: Nuclear Expression of KLF6 Tumor Suppressor Factor Is Highly Associated with Overexpression of ERBB2 Oncoprotein in Ductal Breast Carcinomas

doi: 10.1371/journal.pone.0008929

Figure Lengend Snippet: The immunohistochemical staining intensity for KLF6 (nuclear and cytoplasmic) and c-erbB2 (cytoplasmic membrane) is represented as scores used a 0.0–4.0 scale estimated over a characteristic cell cluster of each tissue. The scores estimation was obtained as described , (see ). A score of 1.0 represent less than 10% of positive labeled cells and was set as the cutoff value. A. Scatter plot analysis of nuclear KLF6 versus cytoplasmic KLF6. The oval includes positive tissue for both staining patterns. B. Scatter plot analysis of nuclear KLF6 versus ERBB2 immunostains. Filled lines settled at 0.0 and 1.0 score indicate cutoff values and partite four populations determined by the KLF6 and ERBB2 staining. The percentage of each population is represented into a gray circle. Especially for the double-negative population (minus 1.0 and 0.0 scores) a point could represent two or more cases.

Article Snippet: A significant subpopulation of the ductal breast tumor collection [44% (21/48)] showed positive immunostain for nuclear KLF6 and ERBB2 overexpression (Chi-square and Fisher exact tests p values equal to 0.005 and 0.003, respectively; ); analysis of the tumor population overexpressing only ERBB2 revealed that the seventy-eight percent (21/27) of ductal breast tumor tissues expressed nuclear KLF6 ( ).

Techniques: Immunohistochemical staining, Staining, Membrane, Labeling

Journal: PLoS ONE

Article Title: Nuclear Expression of KLF6 Tumor Suppressor Factor Is Highly Associated with Overexpression of ERBB2 Oncoprotein in Ductal Breast Carcinomas

doi: 10.1371/journal.pone.0008929

Figure Lengend Snippet: Analysis of the nuclear KLF6 expression along with the Estrogen receptor alpha status and HER2-ERBB2 overexpression in breast tumor tissues.

Article Snippet: A significant subpopulation of the ductal breast tumor collection [44% (21/48)] showed positive immunostain for nuclear KLF6 and ERBB2 overexpression (Chi-square and Fisher exact tests p values equal to 0.005 and 0.003, respectively; ); analysis of the tumor population overexpressing only ERBB2 revealed that the seventy-eight percent (21/27) of ductal breast tumor tissues expressed nuclear KLF6 ( ).

Techniques: Expressing, Over Expression

Journal: PLoS ONE

Article Title: Nuclear Expression of KLF6 Tumor Suppressor Factor Is Highly Associated with Overexpression of ERBB2 Oncoprotein in Ductal Breast Carcinomas

doi: 10.1371/journal.pone.0008929

Figure Lengend Snippet: Clinicopathological parameters of ERBB2-overexpressing ductal breast tumors and nuclear KLF6.

Article Snippet: A significant subpopulation of the ductal breast tumor collection [44% (21/48)] showed positive immunostain for nuclear KLF6 and ERBB2 overexpression (Chi-square and Fisher exact tests p values equal to 0.005 and 0.003, respectively; ); analysis of the tumor population overexpressing only ERBB2 revealed that the seventy-eight percent (21/27) of ductal breast tumor tissues expressed nuclear KLF6 ( ).

Techniques:

Journal: Drug Design, Development and Therapy

Article Title: miR-125b acts as a tumor suppressor in chondrosarcoma cells by the sensitization to doxorubicin through direct targeting the ErbB2-regulated glucose metabolism

doi: 10.2147/DDDT.S90530

Figure Lengend Snippet: Overexpression of miR-125b in chondrosarcoma cells inhibits cells growth rate and increases the sensitivity to doxorubicin. Notes: ( A ) Transfection of pre-miR-125b into JJ012, CH-2879, and SW1353 cells; the expressions of miR-125b were measured by qPCR. ( B ) Overexpression of miR-125b inhibits the JJ012, CH-2879, and SW1353 cells growth rates. Cells were transfected with pre-miR-125b for 48 hours, and then were plated into 48-well plates for the cell growth assays. ( C ) JJ012, CH-2879, and SW1353 cells were transfected with negative control and pre-miR-125b for 48 hours; the cells were plated into 48-well plates for the treatments with doxorubicin at indicated concentrations for 48 hours, followed by the cell viability assays. Columns, mean of three independent experiments; bars, SE. * P <0.05; ** P <0.01; *** P <0.001.

Article Snippet: Overexpression vectors containing wild-type ErbB2 (RC212583) and LDHA (RC228293) were purchased from www.origene.com .

Techniques: Over Expression, Transfection, Negative Control

Journal: Drug Design, Development and Therapy

Article Title: miR-125b acts as a tumor suppressor in chondrosarcoma cells by the sensitization to doxorubicin through direct targeting the ErbB2-regulated glucose metabolism

doi: 10.2147/DDDT.S90530

Figure Lengend Snippet: Overexpression of miR-125b in chondrosarcoma cells downregulates glucose metabolism. Notes: ( A ) Glucose uptake and ( B ) lactate product were measured in miR-125b overexpressing JJ012 (left) and CH-2879 (right) cells compared with negative control. ( C ) Western blotting experiments showed that the expressions of HK II, PDK1, and LDHA were downregulated in miR-125b overexpressing JJ012 (left) and CH-2879 (right) cells compared with negative control. β-actin was used as a loading control. Columns, mean of three independent experiments; bars, SE. * P <0.05.

Article Snippet: Overexpression vectors containing wild-type ErbB2 (RC212583) and LDHA (RC228293) were purchased from www.origene.com .

Techniques: Over Expression, Negative Control, Western Blot, Control

Journal: Drug Design, Development and Therapy

Article Title: miR-125b acts as a tumor suppressor in chondrosarcoma cells by the sensitization to doxorubicin through direct targeting the ErbB2-regulated glucose metabolism

doi: 10.2147/DDDT.S90530

Figure Lengend Snippet: Restoration of ErbB2 in miR-125b overexpressing cells recovers the glucose metabolism and doxorubicin sensitivity. Notes: ( A ) JJ012 cells were transfected with 100 nM pre-miR-negative control and pre-miR-125b for 48 hours, followed by transfection with vector control and overexpression vector containing wild-type ErbB2 for 24 hours, and then cells were collected and prepared for Western blotting with antibody against ErbB2, HK II, PDK1, and LDHA. β-actin was used as a loading control. ( B ) JJ012 cells were transfected with pre-miR-125b and ErbB2 as described in ( A ), then the glucose uptake (left) and lactate product (right) were checked. ( C ) JJ012 cells were transfected with pre-miR-125b and ErbB2 as described in ( A ); cells were collected and replaced in 48-well plates for overnight, followed by doxorubicin treatments at the indicated concentrations for 48 hours. Cells were analyzed by cell viability assays. ( D ) The JJ012 cells were transfected with control siRNA or siErbB2 for 48 hours, and then cells were collected for Western blot analysis (middle) and the measurements of glucose uptake and lactate product. Columns, mean of three independent experiments; bars, SE. * P <0.05; ** P <0.01.

Article Snippet: Overexpression vectors containing wild-type ErbB2 (RC212583) and LDHA (RC228293) were purchased from www.origene.com .

Techniques: Transfection, Negative Control, Plasmid Preparation, Control, Over Expression, Western Blot

Journal: Drug Design, Development and Therapy

Article Title: miR-125b acts as a tumor suppressor in chondrosarcoma cells by the sensitization to doxorubicin through direct targeting the ErbB2-regulated glucose metabolism

doi: 10.2147/DDDT.S90530

Figure Lengend Snippet: Overexpression of miR-125b resensitizes doxorubicin resistant chondrosarcoma cells through the inhibition of glucose metabolism. Notes: ( A ) Overexpression of miR-125b resensitized doxorubicin resistant cells. Cells were transfected with pre-miR-125b for 48 hours and then were treated with doxorubicin at indicated concentrations for 48 hours, followed by the measurement of cell viability. ( B ) Western blotting experiments showed the overexpression of miR-125b in JJ012 doxorubicin resistant cells decreased the expressions of ErbB2, HK II, PDK1, and LDHA to the same levels as those of JJ012 parental cells. ( C ) Glucose uptake (left) and lactate product (right) results showed the overexpression of miR-125b in JJ012 doxorubicin resistant cells decreased the glucose metabolism to the same levels as those of JJ012 parental cells. ( D ) Exogenous overexpression of LDHA into miR-125b pretransfected JJ012 parental cells (left) showed resistant to doxorubicin treatments at the indicated concentrations for 48 hours (right). Columns, mean of three independent experiments; bars, SE. * P <0.05; ** P <0.01. Abbreviation: Doxo R, Doxo resistant.

Article Snippet: Overexpression vectors containing wild-type ErbB2 (RC212583) and LDHA (RC228293) were purchased from www.origene.com .

Techniques: Over Expression, Inhibition, Transfection, Western Blot